Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab
{{output}}
Approximately 60% of human epidermal growth factor receptor 2-negative (HER2-) breast cancers (BCs) are HER2-low [immunohistochemistry (IHC) 1+ or 2+/in situ hybridization (ISH)-]. The proportion of BC patients with hormone receptor-positive (HR+)/HER2- are mo... ...
